Shares of Mural Oncology plc (NASDAQ:MURA – Get Free Report) traded down 1.9% during trading on Thursday . The stock traded as low as $3.44 and last traded at $3.53. 147,884 shares traded hands during trading, a decline of 44% from the average session volume of 262,671 shares. The stock had previously closed at $3.60.
Analyst Ratings Changes
Separately, Morgan Stanley began coverage on shares of Mural Oncology in a research report on Thursday, April 4th. They set an “overweight” rating and a $13.00 price target on the stock.
Check Out Our Latest Analysis on Mural Oncology
Mural Oncology Stock Performance
Mural Oncology (NASDAQ:MURA – Get Free Report) last issued its earnings results on Tuesday, March 26th. The company reported ($3.57) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Mural Oncology plc will post -10.63 earnings per share for the current fiscal year.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Read More
- Five stocks we like better than Mural Oncology
- Election Stocks: How Elections Affect the Stock Market
- MarketBeat Week in Review – 4/22 – 4/26
- Why Are Stock Sectors Important to Successful Investing?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are Dividend Champions? How to Invest in the Champions
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
